Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06344845
Status:
RECRUITING
Last Update Posted:
2024-04-03
First Post:
2024-03-28
Brief Title:
Clinical Study of 18F PM-PBB3 PET Imaging of Tau Protein in Neurodegenerative Diseases
Sponsor:
Peking Union Medical College Hospital
Organization:
Peking Union Medical College Hospital
Study Overview
Official Title:
Clinical Study of 18F PM-PBB3 PET Imaging of Tau Protein in Neurodegenerative Diseases
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In terms of the diagnostic technology of brain neurodegenerative diseases the injection of positron tracers into the human body so that it can combine with the corresponding protein and show its distribution through PET imaging is a mature technology in the industry At present several research groups around the world are working on the development and clinical efficacy evaluation of their respective tau imaging agent compoundsThis clinical research project intends to display the abnormal changes of tau protein in living brain through 18FPM-PBB3 PET imaging which is a second-generation tracer further optimized on the basis of 11CPBB3 and has the advantages of closer binding to tau protein entanglement and less non-specific binding than similar imaging agents Better image quality and a wider range of clinical applications
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None